Fintel on MSN1d
JP Morgan Initiates Coverage of Camp4 Therapeutics (CAMP) with Overweight Recommendation
Fintel reports that on November 5, 2024, JP Morgan initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a Overweight ...
Fintel on MSN1d
Leerink Partners Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation
Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...
The Motley Fool2d
Camp4 Therapeutics (NASDAQ: CAMP)
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...
Analysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), NeoGenomics (NEO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Century Therapeutics (IPSC – Research ...
Investing2d
William Blair upbeat on CAMP4 shares with Outperform rating
Tuesday, William Blair initiated coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) shares with an Outperform rating and a fair value estimate of $27.43 per share. The firm recognized CAMP4's ...
Morningstar6d
Camp4 Therapeutics Corp CAMP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Investing2d
Leerink sets stock target for CAMP4, cites broad UCD treatment potential
Tuesday, Leerink Partners initiated coverage on shares of CAMP4 Therapeutics Corp (NASDAQ: CAMP) with an Outperform rating and a price target of $17.00. The coverage is based on the potential of the ...
MedCity News3d
Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug
Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront ...
Yahoo Finance13d
CAMP4 THERAPEUTICS CORPORATION (CAMP)
Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings. Individual or entity Most recent transaction Date Shares owned as of transaction date 5AM PARTNERS VI, LLC ...
Morningstar6d
Camp4 Therapeutics Corp
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing2d
William Blair upbeat on CAMP4 shares with Outperform rating
Tuesday, William Blair initiated coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) shares with an Outperform rating and a fair value estimate of $27.43 per share. The firm recognized CAMP4's ...